AESARA Appoints Denise Sánchez as Vice President of Regulatory Counsel & Compliance Strategies AESARA, a leading Value & Access agency, has announced the appointment of Denise Sánchez, JD, MS, MA,…
Vyriad Receives FDA Clearance to Begin Phase 1 Trial of VV169 In Vivo CAR T Therapy for Multiple Myeloma Vyriad, Inc., a clinical-stage biotechnology company developing targeted genetic therapies for…
Lightcast Appoints Sarah Taylor, PhD, as Vice President of Science to Advance Envisia Single-Cell Analysis Platform Lightcast, a life science tools company focused on functional single-cell analysis, has appointed Sarah…
Retension Pharmaceuticals Forms Scientific Advisory Board to Support RTN-001 Phase 2b Hypertension Development Retension Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on developing medicines for hypertension and other cardiovascular diseases,…
SonoThera Appoints Adam J. Shaywitz, M.D., Ph.D., as Chief Medical Officer to Advance Genetic Medicine Pipeline SonoThera, a biotechnology company developing next-generation genetic medicines designed to address the underlying causes…
Vyome Holdings Appoints Jerry Leonard as Chief Financial Officer to Strengthen Financial Operations and Support Pipeline Development Vyome Holdings, Inc. (Nasdaq: HIND), a clinical-stage biopharmaceutical company developing differentiated therapies for…
Family Heart Foundation Study Shows Machine Learning Model Can Help Identify ASCVD Patients at Higher Risk of Elevated Lp(a) The Family Heart Foundation, a leading research, education and advocacy organization…
NImmune Biopharma to Present Clinical and Preclinical Data on NIM-1324 at ACG 2026, Highlighting LANCL2 Potential in Difficult-to-Treat IBD NImmune Biopharma, a private, late-stage precision inflammation and immunology (I&I) biopharmaceutical…
Quanterix Appoints Dr. Yuri Fesko as Chief Medical Officer to Advance Diagnostics Strategy Quanterix Corporation, a global leader in precision biomarker science, has announced the appointment of physician executive Dr.…
Bristol Myers Squibb Reports Positive Phase 2 QUINTESSENTIAL Results for Arlo-Cel in Heavily Pretreated Multiple Myeloma Bristol Myers Squibb (NYSE: BMY) announced positive Phase 2 results from the registrational QUINTESSENTIAL…
IMDELLTRA® Plus IMFINZI® Shows Landmark Overall Survival Benefit in First-Line Extensive-Stage Small Cell Lung Cancer Amgen (NASDAQ: AMGN) announced landmark results from the Phase 3 DeLLphi-305 study, reporting that the…
Novartis Reports HARBOR Phase 3 Study of Del-Desiran in Myotonic Dystrophy Type 1 Misses Primary Endpoint Novartis announced that the global Phase 3 HARBOR study evaluating del-desiran in people living…